Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers - Wikidata - wikimedia - TriplyDB

Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers

Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers

http://www.wikidata.org/entity/Q34431915

about

Transfer of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected Newborns Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity.Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy.Biomarkers from late pregnancy to 6 weeks postpartum in HIV-infected women who continue versus discontinue antiretroviral therapy after delivery.Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women.Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation

P2860

Q28070259-A0E8E033-A01F-48C2-A54B-57034B9EC4C0 Q35127830-A86AB69E-293D-4EE1-84D4-95CBC63D367B Q36072127-254734E8-4750-4FBB-ADA7-3397A867278E Q37404428-DF4CF41F-7CE5-4746-AC15-AB6687CD0487 Q38750453-E8801DCC-AA15-49C8-9D07-8FF1B04A4CEE Q41665214-57CF6AC5-F085-46EB-A3F4-500B27793D7C

P2860

Correlation of immune activation during late pregnancy and early postpartum with increases in plasma HIV RNA, CD4/CD8 T cells, and serum activation markers

http://www.wikidata.org/entity/Q34431915

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Correlation of immune activati ...... , and serum activation markers

@ast

Correlation of immune activati ...... , and serum activation markers

@en

Correlation of immune activati ...... , and serum activation markers

@nl

type

label

Correlation of immune activati ...... , and serum activation markers

@ast

Correlation of immune activati ...... , and serum activation markers

@en

Correlation of immune activati ...... , and serum activation markers

@nl

prefLabel

Correlation of immune activati ...... , and serum activation markers

@ast

Correlation of immune activati ...... , and serum activation markers

@en

Correlation of immune activati ...... , and serum activation markers

@nl

P1433

Q34431915-45F57858-9EC3-43DB-9D36-14989B79A849

P1476

Q34431915-5BB64F59-75BC-477B-9F13-422FACCB8502

P2093

Q34431915-0E7D007A-FC54-4353-9C81-405569DAEE22

Q34431915-47AACD98-475F-4E88-A379-538009A25DF7

Q34431915-4D31218F-D989-4CBE-B2BC-0F1726D671A5

Q34431915-7BAD7E09-13AB-4682-8314-F8156DFD4B91

Q34431915-96994BAA-A7A9-459C-BB71-34DB1A34ED15

Q34431915-9F47D411-DD0A-429C-909D-60AF0F3AD5B2

Q34431915-DF0010CC-03CD-43D0-BBE5-872A4F476B55

P2860

Q34431915-0BC48D35-9F2D-4F65-8DE5-E34148CDB3D7

Q34431915-15521D21-3061-41DC-9EA8-3D68B89FDD6F

Q34431915-2B2611FC-1E23-4288-893A-E2A92ABBEE36

Q34431915-2CC6AE70-C372-43FB-854F-CD31050B6428

Q34431915-37FE5175-9D17-4EBA-A73F-F17CC90ADF6C

Q34431915-38604178-B292-4B1C-87A9-437CFBB00D58

Q34431915-5464CFC6-9EA9-4A61-8758-2D3456559A94

Q34431915-6489A8F5-1EF4-419F-8D1C-ACEBC875F37A

Q34431915-6E0EF0CD-6826-44EB-A15D-A20B569F3AF8

Q34431915-77A0EAFD-A1B4-437B-85D3-FE1B6784548D

P304

Q34431915-5D7EBA88-83F1-48EA-BE79-458D4B3D9577

P31

Q34431915-6BFDB818-6A43-405F-B9D7-5298DA490C48

P356

Q34431915-0692F4A4-58D2-4031-85F1-CF6A3B8ABEC8

P433

Q34431915-D32AD4D2-5979-4EB1-A28F-8E19B344215E

P478

Q34431915-95D110A7-D9E0-43DD-9813-4F7FAD7CA086

P577

Q34431915-4B2C6602-93E5-4195-96CD-C87670853A38

P698

Q34431915-F636AACF-8C32-49DD-8E53-F82B5005D36F

P921

Q34431915-EC1D9CEA-3E97-4958-80C8-535E8F689FA0

P932

Q34431915-FE506B55-74EA-49BB-9548-730D7BEC4319

P356

P1433

Clinical and Vaccine Immunology

P1476

Correlation of immune activati ...... , and serum activation markers

@en

P2093

Christel H Uittenbogaart

http://www.w3.org/2001/XMLSchema#string

Hong-Ha M Truong

http://www.w3.org/2001/XMLSchema#string

Maryanne Dillon

http://www.w3.org/2001/XMLSchema#string

Myung S Sim

http://www.w3.org/2001/XMLSchema#string

Ruth Dickover

http://www.w3.org/2001/XMLSchema#string

Susan F Plaeger

http://www.w3.org/2001/XMLSchema#string

Yvonne J Bryson

http://www.w3.org/2001/XMLSchema#string

P2860

Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials.

Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.

Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

beta-2 Microglobulin values among human immunodeficiency virus (HIV)-negative, HIV-positive asymptomatic, and HIV-positive symptomatic Ugandans.

Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

P304

2024-2028

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/CVI.00088-10

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20980480

http://www.w3.org/2001/XMLSchema#string

P921

postpartum period

P932

3008186

http://www.w3.org/2001/XMLSchema#string